Combining with the fact that DNASE1L3 is generally downregulated across multiple cancers (The Cancer Genome Atlas, TCGA database) [34], inactivation of DNASE1L3 is proposed to be the reason underlying the aberrant cfDNA profile in cancer patients. This evidence concerns the gene DNASE1L3 and cancer.